重磅！FierceBiotech's 2017 Fierce 15

每年，闻名行业的FierceBiotech都会对数百家公司进行评估，

发现通过远见卓识和管理专长

改变医生治疗疾病、提高药物开发过程的公司。

这些公司是行业里的佼佼者，

是冉冉升起的明日之星！

2017年8月12日，

药时代发布了文章

汇总了之前获得殊荣的公司。

今天，FierceBiotech发布2017年名单

2017 Fierce 15

15家新上榜的公司是：

Aravive Biologics

Aravive's leading program is focused on blocking the GAS6/AXL pathway

Axial Biotherapeutics

Axial is working to treat CNS disorders in a three-pronged approach through the gut-brain connection.

BlackThorn Therapeutics

JLABS alumnus BlackThorn aims to succeed in the neuro territory by using physiological measures to better define the diseases and their populations.

Gritstone Oncology

Gristone is working to apply next-generation sequencing, bioinformatics and algorithms to the creation of new cancer immunotherapies.

Magenta Therapeutics

Magenta Therapeutics works to improve hematopoietic stem cell transplantation so that it can be used in more patients.

PMV Pharma

PMV Pharma tries to tackle cancer by targeting the mutated p53 protein without negatively affecting normal versions of it.

PsiOxus Therapeutics

PsiOxus’ pipeline is built around enadenotucirev, a virus singled out for its ability to kill tumor cells.

Relay Therapeutics

Relay’s backer Third Rock Ventures thinks showing motion will reveal new ways to treat diseases, with frequently mutated oncogenes as their first step.

Repare Therapeutics

CRISPR has made it possible for Repare to increase both the scale and precision of the search for drug targets that can induce synthetic lethality in cancer cells.

Rubius Therapeutics

For Rubius, pulling the rug out from under CAR-Ts is just one item on its to-do list.

Tango Therapeutics

Tango gestated within Third Rock Ventures for about 18 months, building on an idea.

Turnstone Biologics

Turnstone's oncolytic virus was discovered through Maraba, found in Brazilian sand-flies.

Vir Biotechnology

Vir focuses on developing vaccines and drugs to cure infectious diseases for which there are currently scarce treatments.

Vivet Therapeutics

Vivet is harnessing the power of gene therapy to target Wilson disease and other rare genetic disorders.

Vividion Therapeutics

Vividion seeks to deploy its synthetic and proteomic chemistry platforms to identify druggable targets.

（The above information is from FierceBioTech. All copyrights belong to the owner. Many thanks!）

药时代热烈祝贺！

DrugTimes Warmly Congratulates the Winners！

—— 欢迎阅读近3个月内10,000+文章！——

欢迎联系我们！[e-mail]